Specific antibody combined with coronavirus SARS-CoV-2 and SARS-CoV nucleocapsid protein and application thereof
The invention discloses a specific antibody capable of being combined with a coronavirus SARS-CoV-2 and a coronavirus SARS-CoV nucleocapsid protein (Nucleocapsid protein), and an application of the specific antibody capable of being combined with the coronavirus SARS-CoV-2 and the Nucleocapsid protein. The sequences of the CDRs of the antibody disclosed by the invention are as shown in SEQ ID NO. 1 to SEQ ID NO. 6. The antibody provided by the invention contains CDRs with a specific sequence, can be specifically combined with SARS-CoV-2 and SARS-CoV nucleocapsid proteins, and has a weak binding reaction with a nucleocapsid protein of another highly pathogenic coronavirus MERS-CoV at the same time. The antibody provided by the invention is strong in targeting property and high in binding activity, and the antibody prepared by the preparation method provided by the invention is high in purity and can be prepared on a large scale. On the whole, the antibody disclosed by the invention can be used for developing and optimizing an SARS-CoV and SARS-CoV-2 infection detection method..
| Medienart: |
|
|---|
Patent| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Europäisches Patentamt - (2023) vom: 01. Dez. Zur Gesamtaufnahme - year:2023 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
ZHANG LU [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Anmerkungen: |
Source: www.epo.org (no modifications made), First posted: 2023-12-01, Last update posted on www.tib.eu: 2024-02-05, Last updated: 2024-02-09 |
|---|
| Patentnummer: |
CN117143227 |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
EPA019149417 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | EPA019149417 | ||
| 003 | DE-627 | ||
| 005 | 20240209083151.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240209s2023 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)EPA019149417 | ||
| 035 | |a (EPA)CN117143227 | ||
| 035 | |a (EPA)88899492 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 0 | |a ZHANG LU |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Specific antibody combined with coronavirus SARS-CoV-2 and SARS-CoV nucleocapsid protein and application thereof |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Source: www.epo.org (no modifications made), First posted: 2023-12-01, Last update posted on www.tib.eu: 2024-02-05, Last updated: 2024-02-09 | ||
| 520 | |a The invention discloses a specific antibody capable of being combined with a coronavirus SARS-CoV-2 and a coronavirus SARS-CoV nucleocapsid protein (Nucleocapsid protein), and an application of the specific antibody capable of being combined with the coronavirus SARS-CoV-2 and the Nucleocapsid protein. The sequences of the CDRs of the antibody disclosed by the invention are as shown in SEQ ID NO. 1 to SEQ ID NO. 6. The antibody provided by the invention contains CDRs with a specific sequence, can be specifically combined with SARS-CoV-2 and SARS-CoV nucleocapsid proteins, and has a weak binding reaction with a nucleocapsid protein of another highly pathogenic coronavirus MERS-CoV at the same time. The antibody provided by the invention is strong in targeting property and high in binding activity, and the antibody prepared by the preparation method provided by the invention is high in purity and can be prepared on a large scale. On the whole, the antibody disclosed by the invention can be used for developing and optimizing an SARS-CoV and SARS-CoV-2 infection detection method. | ||
| 650 | 4 | |a bio | |
| 650 | 4 | |a tec | |
| 650 | 4 | |a A61K: Preparations for medical, dental, or toilet purposes (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms a61j0003000000;chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles a61l; soap compositions c11d) | |
| 650 | 4 | |a G01N: Investigating or analysing materials by determining their chemical or physical properties (measuring or testing processes other than immunoassay, involving enzymes or microorganisms c12m, c12q) | |
| 650 | 4 | |a A61P: Specific therapeutic activity of chemical compounds or medicinal preparations | |
| 650 | 4 | |a C12N: Microorganisms or enzymes; compositions thereof; propagating, preserving, or maintaining microorganisms; mutation or genetic engineering; culture media (microbiological testing media c12q0001000000) | |
| 650 | 4 | |a C07K: Peptides (peptides containing β-lactam rings c07d;cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, c07d;ergot alkaloids of the cyclic peptide type c07d0519020000; single cell proteins, enzymes c12n;genetic engineering processes for obtaining peptides c12n0015000000) | |
| 650 | 4 | |a che | |
| 650 | 4 | |a 615 | |
| 700 | 0 | |a DAI JUN |4 aut | |
| 700 | 0 | |a WANG YANQUN |4 aut | |
| 700 | 0 | |a ZHANG ZHAOYONG |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Europäisches Patentamt |g (2023) vom: 01. Dez. |
| 773 | 1 | 8 | |g year:2023 |g day:01 |g month:12 |
| 856 | 4 | 0 | |u https://worldwide.espacenet.com/patent/search/family/88899492/publication/CN117143227A1?q=CN117143227 |z kostenfrei |3 Volltext |
| 912 | |a GBV_EPA | ||
| 936 | u | w | |j 2023 |b 01 |c 12 |
| 951 | |a AR | ||
| 952 | |j 2023 |b 01 |c 12 | ||